Enovis Corporation (ENOV)
NYSE: ENOV · Real-Time Price · USD
35.94
+0.38 (1.07%)
Jul 10, 2025, 4:00 PM - Market closed

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Total Medical Technology
2.11B
Log In
Log In
Log In
Log In
Upgrade
Total Medical Technology Growth
18.32%
Log In
Log In
Log In
Log In
Upgrade
U.S. Bracing & Support
469.32M
Log In
Log In
Log In
Log In
Upgrade
U.S. Bracing & Support Growth
5.15%
Log In
Log In
Log In
Log In
Upgrade
U.S. Other P&R
270.74M
Log In
Log In
Log In
Log In
Upgrade
U.S. Other P&R Growth
-1.03%
Log In
Log In
Log In
Log In
Upgrade
International P&R
357.90M
Log In
Log In
Log In
Log In
Upgrade
International P&R Growth
1.63%
Log In
Log In
Log In
Log In
Upgrade
U.S. Reconstructive
505.62M
Log In
Log In
Log In
Log In
Upgrade
U.S. Reconstructive Growth
16.37%
Log In
Log In
Log In
Log In
Upgrade
International Reconstructive
504.05M
Log In
Log In
Log In
Log In
Upgrade
International Reconstructive Growth
81.68%
Log In
Log In
Log In
Log In
Upgrade

Capex by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Other
-
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other
-
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
Prevention & Recovery Capital Expenditures
34.00M
Log In
Log In
Log In
Log In
Upgrade
Prevention & Recovery Capital Expenditures Growth
-
Log In
Log In
Log In
Log In
Upgrade
Reconstructive Capital Expenditures
146.71M
Log In
Log In
Log In
Log In
Upgrade
Reconstructive Capital Expenditures Growth
-
Log In
Log In
Log In
Log In
Upgrade

EBITDA by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Prevention & Recovery Adjusted EBITDA
159.60M
Log In
Log In
Log In
Log In
Upgrade
Prevention & Recovery Adjusted EBITDA Growth
5.07%
Log In
Log In
Log In
Log In
Upgrade
Reconstructive Adjusted EBITDA
216.92M
Log In
Log In
Log In
Log In
Upgrade
Reconstructive Adjusted EBITDA Growth
62.66%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
United States
1.25B
Log In
Log In
Log In
Log In
Upgrade
United States Growth
7.97%
Log In
Log In
Log In
Log In
Upgrade
Foreign Locations
861.95M
Log In
Log In
Log In
Log In
Upgrade
Foreign Locations Growth
37.33%
Log In
Log In
Log In
Log In
Upgrade